ESSA Pharma Investor Relations Material
Latest events
Access the full event backlog
Slides, Transcripts, and Reports from 9,000+ public companies
Latest reports from ESSA Pharma Inc
Access all reports
ESSA Pharma Inc. is a clinical-stage pharmaceutical company primarily focused on the development of novel therapies for the treatment of prostate cancer. The company is pioneering the creation of a new class of drugs known as "anitens," which are designed to disrupt the androgen receptor signaling pathway, a key driver in the progression of prostate cancer. ESSA's lead clinical candidate, masofaniten (formerly known as EPI-7386), targets the N-terminal domain of the androgen receptor, aiming to offer a novel approach for patients with castration-resistant prostate cancer and metastatic castration-resistant prostate cancer, especially those who have developed resistance to current anti-androgen therapies. The company is headquartered in Vancouver, Canada, and its shares are listed on the Nasdaq.
Key slides for ESSA Pharma Inc
Corporate Presentation
ESSA Pharma Inc
Corporate Presentation
ESSA Pharma Inc
Latest articles
Companies That Had Their IPO in 2019: Bull Market and Tech Dominance
Discussing the stock and IPO market in 2019, and the factors that led to the overall bullish performance of stocks during the year.
3 May 2024
Microsoft's Journey to Becoming the World's Most Valuable Company
Explore Microsoft's rise from a garage startup to the world's most valuable company, highlighting Bill Gates' role in shaping the digital revolution.
3 May 2024
Bill Gates: The Man Who Put a Computer in Every Home
Explore the life of Bill Gates, from co-founding Microsoft to global philanthropy, and his lasting impact on the world.
2 May 2024
Ticker symbol
Country
🇺🇸 United States